2. Metabolic Disease

Metabolic Disease

Metabolic Disease

Related Products

PDF 53.7 MB

Metabolic diseases is defined by a constellation of interconnected physiological, biochemical, clinical, and metabolic factors that directly increases the risk of cardiovascular disease, type 2 diabetes mellitus, and all cause mortality. Associated conditions include hyperuricemia, fatty liver (especially in concurrent obesity) progressing to nonalcoholic fatty liver disease, polycystic ovarian syndrome (in women), erectile dysfunction (in men), and acanthosis nigricans. Metabolic disease modeling is an essential component of biomedical research and a mandatory prerequisite for the treatment of human disease. Somatic genome editing using CRISPR/Cas9 might be used to establish novel metabolic disease models.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-116977
    Binifibrate 69047-39-8 98%
    Binifibrate is an active compound and has a beneficial effect on lipoprotein metabolism. Binifibrate can be used for the research of hyperlipidemia.
    Binifibrate
  • HY-117075
    BI-44847 421592-30-5 98%
    BI-44847 is a selective and orally active SGLT2 inhibitor. BI-44847 can increase UGE and decrease HbA1c levels. BI-44847 shows improvement in fasting and fed glucose levels. BI-44847 can be studied in research on type 2 diabetes mellitus (T2DM).
    BI-44847
  • HY-117084
    BMS-210285 344607-69-8 98%
    BMS-210285 is a highly selective agonist for the 3 receptor. BMS-210285 has a Ki of 9 nM at the human 3-adrenoceptor. BMS-210285 possesses a 3 intrinsic activity of 83% relative to isoproterenol. BMS-210285 can be studied for obesity and type 2 diabetes research.
    BMS-210285
  • HY-117119
    VER-3323 259857-99-3 98%
    VER-3323 is an oral active 5-HT2C agonist and belongs to the class of indoline analogs. VER-3323 reduces food intake in rats by inducing swallowing dysfunction, with no significant impact on energy expenditure generated through thermogenesis or exercise. VER-3323 can be utilized in obesity research.
    VER-3323
  • HY-117133
    Nesvategrast 1621332-91-9 98%
    Nesvategrast (SF0166) is a potent and selective αvβ3 antagonist with IC50 values of 0.6 nM, 8 nM, and 13 nM for αvβ3, αvβ6, and αvβ8, respectively. Nesvategrast inhibits cellular adhesion to vitronectin across human, rat, rabbit, and dog cell lines with IC50 values of 7.6 pM to 76 nM. Nesvategrast decreases neovascularization in the oxygen-induced retinopathy mouse model.
    Nesvategrast
  • HY-117172
    CP320626 186430-23-9 98%
    CP320626 is a potent inhibitor of human liver glycogen phosphorylase (IC50=205 nM). CP320626 reduces blood glucose in diabetic mice without changing plasma insulin levels. CP320626 can be used in the study of type 2 diabetes.
    CP320626
  • HY-117178
    TA 0910 acid-type 103300-77-2 99.85%
    TA 0910 acid-type is a metabolite of TA 0910. TA-0910 is a metabolically stable analogue of thyrotropin releasing hormone (TRH).
    TA 0910 acid-type
  • HY-117182
    LG190178 233268-81-0 98%
    LG190178 is a non-steroidal vitamin D receptor (VDR) ligand that can induce the formation of heterodimer complexes between VDR and retinoid X receptor (RXR), stabilizing the agonistic conformation of the VDR ligand-binding domain and promoting its interaction with co-activators. LG190178 has functions in regulating calcium homeostasis, bone mineralization, as well as cell proliferation, differentiation, and apoptosis, making it useful for research in psoriasis, osteoporosis, and cancer.
    LG190178
  • HY-117186
    Bis-propargyl-PEG6 400775-35-1
    Bis-propargyl-PEG6 is a PEG-based PROTAC linker used in the synthesis of PROTACs. Bis-propargyl-PEG6 can be used to synthesize the polymer linked multimers of guanosine-3', 5'-cyclic monophosphates. Bis-propargyl-PEG6 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
    Bis-propargyl-PEG6
  • HY-117198
    CHIR-21208 206275-65-2 98%
    CHIR-21208 is a highly selective glycogen synthase kinase-3 (GSK-3) inhibitor. CHIR-21208 is promising for research of neurodegenerative disorders like Alzheimer's disease and type 2 diabetes.
    CHIR-21208
  • HY-117212
    Ronopterin 206885-38-3 98%
    Ronopterin (VAS203) is a NO Synthase inhibitor. Ronopterin can be used in research on diseases of the urogenital system and the nervous system.
    Ronopterin
  • HY-117339
    AD-5467 112808-22-7 98%
    AD-5467 is a potent and selective aldose reductase inhibitor. AD-5467 exhibits antidiabetic effect. AD-5467 can be used for the research of metabolic disease, such as diabetes.
    AD-5467
  • HY-117372
    DFL23448 1445753-16-1 98%
    DFL23448 is a selective transient receptor potential melastatin-8 (TRPM8) antagonist. DFL23448 shows IC50 values of 10 and 21 nM in hTRPM8 human embryonic kidney 293 cells activated by Cooling Agent 10 or cold. DFL23448 has limited activity (IC50 >10 μM) at transient receptor potential vanilloids TRPV1, TRPA1, or TRPV4 or at various G protein-coupled receptors. DFL23448 can modify bladder function and reduce bladder overactivity in awake rats.
    DFL23448
  • HY-117390
    FR-181074 184147-65-7 98%
    FR-181074 is a selective and orally active PDE V inhibitor. FR-181074 can specifically block PDE V to inhibit the degradation of cyclic guanosine monophosphate (cGMP) in order to relax smooth muscle. FR-181074 can be used for the researches of cardiovascular disease and endocrinology, such as hypertension and erectile dysfunction.
    FR-181074
  • HY-117406
    Clencyclohexerol 157877-79-7
    Clencyclohexerol is a β2 adrenergic receptor agonist. Clencyclohexerol can be used as a growth promoter in animals.
    Clencyclohexerol
  • HY-117428
    INU-101 1513828-41-5 98%
    INU-101 is a potent, selective and orally active 11β-hydroxysteroid dehydrogenase (11β-HSD) type 1 inhibitor. INU-101 has highly potent inhibitory activity in mouse, monkey and human 11β-HSD1, derived from liver microsomes. INU-101 can enhance insulin sensitivity and lower the fasting blood glucose level. INU-101 can be used for the research of metabolic disease, such as diabetes.
    INU-101
  • HY-117437
    Azintamide 1830-32-6 98%
    Azintamide (Bilipurum) can be used for the research of psoriasis vulgaris, dyspepsia and other conditions.
    Azintamide
  • HY-117459
    E-3030 free acid 478926-45-3 98%
    E-3030 free acid is a potent dual activator of peroxisome proliferator-activated receptor (PPAR) alpha and PPARgamma, exhibiting significant antidiabetic and lipid-modulating effects. E-3030 decreases blood glucose, triglyceride, non-esterified fatty acids, and insulin levels, while increasing blood adiponectin levels. E-3030 improves glucose tolerance and shows remarkable triglyceride- and non-high-density lipoprotein cholesterol-lowering effects in animal models.
    E-3030 free acid
  • HY-117527
    L742791 159182-18-0 98%
    L742791 is a β3-AR agonist. L742791 elicits lipolytic response in isolated nonhuman primate adipocytes.
    L742791
  • HY-117581
    L-669,262 130468-11-0 98%
    L-669,262, a potent inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, with an IC50 of 0.10 ng/mL for rat liver HMG-CoA.
    L-669,262
Cat. No. Product Name / Synonyms Application Reactivity